000099816 001__ 99816
000099816 005__ 20230519145418.0
000099816 0247_ $$2doi$$a10.1007/s10096-020-04139-5
000099816 0248_ $$2sideral$$a123386
000099816 037__ $$aART-2021-123386
000099816 041__ $$aeng
000099816 100__ $$aFuentes, A.
000099816 245__ $$aAntibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain
000099816 260__ $$c2021
000099816 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099816 5203_ $$aAim: To evaluate the serological response against SARS-CoV-2 in a multicenter study representative of the Spanish COVID pandemic.
Methods: IgG and IgM + IgA responses were measured on 1466 samples from 1236 Spanish COVID-19 patients admitted to the hospital, two commercial ELISA kits (Vircell SL, Spain) based on the detection of antibodies against the viral spike protein and nucleoprotein, were used.
Results: Approximately half of the patients presented antibodies (56.8% were IgM + IgA positive and 43.0% were IgG positive) as soon as 2 days after the first positive PCR result. Serological test positivity increased with time from the PCR test, and 10 days after the first PCR result, 91.5% and 88.0% of the patients presented IgM + IgA and IgG antibodies, respectively.
Conclusion: The high values of sensitivity attained in the present study from a relatively early period of time after hospitalization support the use of the evaluated serological assays as supplementary diagnostic tests for the clinical management of COVID-19.
000099816 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000099816 590__ $$a5.103$$b2021
000099816 592__ $$a1.205$$b2021
000099816 594__ $$a6.7$$b2021
000099816 591__ $$aMICROBIOLOGY$$b49 / 138 = 0.355$$c2021$$dQ2$$eT2
000099816 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000099816 591__ $$aINFECTIOUS DISEASES$$b41 / 96 = 0.427$$c2021$$dQ2$$eT2
000099816 593__ $$aInfectious Diseases$$c2021$$dQ1
000099816 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099816 700__ $$aSerrano-Conde, E.
000099816 700__ $$aRoldán, C.
000099816 700__ $$0(orcid)0000-0001-5134-1006$$aBenito-Ruesca, R.$$uUniversidad de Zaragoza
000099816 700__ $$aMejías, G.
000099816 700__ $$aSampedro, A.
000099816 700__ $$aMarch-Roselló, G.
000099816 700__ $$aFernández-Natal, I.
000099816 700__ $$aEsperalba, J.
000099816 700__ $$aRodríguez, M.J.
000099816 700__ $$aMartínez de Aguirre, P.
000099816 700__ $$aSalas, C.
000099816 700__ $$aRoc, M.L.
000099816 700__ $$aSoria, L.M.
000099816 700__ $$aParra-Grande, M.
000099816 700__ $$aMontero, M.D.
000099816 700__ $$aFernández-Roblas, R.
000099816 700__ $$aFranco-Álvarez de Luna, F.
000099816 700__ $$aLozano, C.
000099816 700__ $$aGarcía, F.
000099816 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000099816 773__ $$g40 (2021), 1343–1349$$pEur. j. clin. microbiol. infect. dis.$$tEUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES$$x0934-9723
000099816 8564_ $$s800549$$uhttps://zaguan.unizar.es/record/99816/files/texto_completo.pdf$$yVersión publicada
000099816 8564_ $$s1978892$$uhttps://zaguan.unizar.es/record/99816/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099816 909CO $$ooai:zaguan.unizar.es:99816$$particulos$$pdriver
000099816 951__ $$a2023-05-18-14:03:17
000099816 980__ $$aARTICLE